The investment is to primarily fund TechInvention’s upcoming state-of-the-art NexGen vaccine manufacturing facility in Navi Mumbai
Renowned Ace Investor Ashish Kacholia has invested in TechInvention Lifecare, a vaccine focussed biotechnology company headquartered in Mumbai.
The investment is to primarily fund TechInvention’s upcoming state-of-the-art NexGen vaccine manufacturing facility in Navi Mumbai. The facility is designed to scale-up and manufacture vaccines from its robust R&D portfolio of vaccine candidates encompassing contemporary platforms such as recombinant subunit, conjugates, VLP (virus-like particles), adenoviral vector & mRNA platforms.
Kacholia said, “We are delighted to support TechInvention in getting life-saving, innovative vaccines commercialised and reach millions across India & beyond. The founders of TechInvention are techno-commercially savvy & together we hope to build a high-quality business over the next few years”.
Syed S Ahmed, Founder and CEO, TechInvention Lifecare, added, “We are delighted to have Mr. Kacholia’s confidence in our vision & his participation is an assurance of the advancement of our Manufacturing facility project titled –‘Global Collaborative Centre for Medical Counter Measures (GCMC’). His belief in our mission reinforces India’s role as a trusted enabler of equitable health solutions for low & middle-income countries (LMICs).”
